Curi Bio integrates human stem cells, systems, and AI-enabled data analytics for the development of new therapeutics.
Curi Bio has raised $10.0M in total funding. The most recent round was Series B. The last funding was announced in December 2025.
Curi Bio's investors include National Institutes of Health, Dynamk Capital, DreamCIS, DS Asset Management, UTC Investment.
Curi Bio is headquartered in Seattle, United States.
Curi Bio integrates human stem cells, systems, and AI-enabled data analytics for the development of new therapeutics.
Curi Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Curi Bio — Funding & Investors." VCBacked, December 2, 2025, https://www.vcbacked.co/company/curi-bio. Accessed September 1, 2026.
VCBacked. (2025). Curi Bio — Funding & Investors. Retrieved September 1, 2026, from https://www.vcbacked.co/company/curi-bio
{{cite web |title=Curi Bio — Funding & Investors |url=https://www.vcbacked.co/company/curi-bio |website=VCBacked |access-date=September 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated